A Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/Day) as Treatment in Patients With Huntington's Disease
Phase of Trial: Phase II
Latest Information Update: 27 Oct 2017
At a glance
- Drugs Laquinimod (Primary)
- Indications Huntington's disease
- Focus Therapeutic Use
- Acronyms LEGATO-HD
- Sponsors Teva Branded Pharmaceutical Products R&D
- 23 Oct 2017 Planned End Date changed from 6 Sep 2018 to 19 Jun 2018.
- 23 Oct 2017 Planned primary completion date changed from 7 Aug 2018 to 19 Jun 2018.
- 10 Jun 2017 Biomarkers information updated